BT/IN/Indo-UK/AMR/03/RKE/2018-19

Government of India Ministry of Science & Technology Department of Biotechnology

Block 2, 7th Floor CGO Complex, Lodhi Road New Delhi 110 003 Dated: 64 09 2018

Admin Order

Sanction of the President is hereby accorded under Rule 18 of the Delegation of Financial Power Rules, 1978 for the implementation of Indo-UK Collaborative project titled "Diagnostics for One health and user Driven Solutions for AMR (DOSA)" by Dr. Ravi Krishnan Elangovan, Indian Institute of Technology, Delhi as the Indian investigator and Dr. Till Bachmann, University of Edinburgh, UK as the UK counterpart for a period of 3 years at a total cost of Rs.495.264 Lakhs (Rupees Four Crores Ninety Five Lakhs Twenty Six Thousand Four Hundred Only) for the Indian component of the project on the terms and conditions as detailed hereunder:

PROJECT TITLE 2.0

"Diagnostics for One heath and user Driven Solutions for AMR (DOSA)"

Investigators : 2.1

Indian Investigators

Principal Investigators	Dr. Ravi Krishnan Elangovan (Co-ordinator) Assistant Professor, Indian Institute of Technology (IIT), Delhi
	Dr. Naresh Kumar Principal Scientist, National Diary Research Institute (NDRI), Kamal
	Dr. Amstabha Bhattacharjee Assistant Professor, Assam University, Silchar, Assam
	Dr. G.K. Sivaraman Principal Scientist, ICAR- Central Institute of Fisheries Technology, Cochin
	Dr. (Mrs.) Debadatta Dhar Associate Professor, Silchar Medical College, Silchar, Assam
	Dr. Salyed Taslimarif CEO and Director, Centre for Cellular and Molecular Platforms (C-CAMP) Bangalore

UK Investigators

Principal Investigators	Dr Till Bachmann, (UK-Cordinator) University of Edinburgh, UK	and the second s
	Prof Stephen Rimmer University of Bradford, UK	
	Prof Xunli Zhang University of Southampton, UK	and the second s
	Dr Alison Prendville	
	Prof Dominic Moron, University of Edinburg, UK Dr Alice Street, University of Edinburgh, UK	

2.2 Project Objectives:

a. Undertake user mapping studies in Human, Dairy and aquaculture environment settings on antibiotics

b. Baseline assessment of resistance pathogens profile using samples from in Human, Dairy and Aquacumure

c. Develop rapid/POC diagnostic assays/ prototypes for UTI, Mastitis, AMR pathogens and anticiot of

d. Socio-economic impact assessment of existing rapid diagnostic tools in the above three settings on

e. Refinement, performance benchmarking, validation and impact assessment of prototype(s) in community settings.

(air Carth